Home › Opioid Overdose › NCT07135323
AvertD Post-Approval Study
RecruitingObservational studyHealthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * ≥18 years of age * Prior to first opioid prescription * Being considered for first oral opioid prescription (4-30 days) * Prescribed AvertD as part of care * Willing and able to complete yearly assessments for 5 years * Signed informed consent Exclusion Criteria: * Planned opioid prescription \<4 or \>30 days * Any condition making participation unsafe or infeasible per investigator judgment
About the study
A Prospective Post-Approval Study of AvertD to Evaluate Device Performance, Prescribing Impact, and Labeling Comprehension in the Intended Use Population
What is being tested
- Opioid Used Disorder Risk Assessment (genetic)
Sponsor: Prescient Medicine Holdings, Inc. · Participants: 4,000 · Started: Nov 15, 2024
Contact the study team
- Amanda Smith, MD · Phone: 800-800-5525
Official record on ClinicalTrials.gov — NCT07135323
Locations in the U.S.
| Indiana | Concentrics Research, Indianapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.